WO2009001214A3 - Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists - Google Patents

Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists Download PDF

Info

Publication number
WO2009001214A3
WO2009001214A3 PCT/IB2008/001745 IB2008001745W WO2009001214A3 WO 2009001214 A3 WO2009001214 A3 WO 2009001214A3 IB 2008001745 W IB2008001745 W IB 2008001745W WO 2009001214 A3 WO2009001214 A3 WO 2009001214A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrimidin
isothiazolo
isoxazolo
derivatives
thieno
Prior art date
Application number
PCT/IB2008/001745
Other languages
French (fr)
Other versions
WO2009001214A2 (en
Inventor
Feng Bi
Mary Theresa Didiuk
Angel Guzman-Perez
David Andrew Griffith
Kevin Kun-Chin Liu
Daniel Patrick Walker
Michael Paul Zawistoski
Original Assignee
Pfizer Prod Inc
Feng Bi
Mary Theresa Didiuk
Angel Guzman-Perez
David Andrew Griffith
Kevin Kun-Chin Liu
Daniel Patrick Walker
Michael Paul Zawistoski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Feng Bi, Mary Theresa Didiuk, Angel Guzman-Perez, David Andrew Griffith, Kevin Kun-Chin Liu, Daniel Patrick Walker, Michael Paul Zawistoski filed Critical Pfizer Prod Inc
Publication of WO2009001214A2 publication Critical patent/WO2009001214A2/en
Publication of WO2009001214A3 publication Critical patent/WO2009001214A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention is directed to novel thieno[2,3-d]pyrimidin-4(3H)-one, isoxazolo[5,4-d]pyrimidin-4(5H)-one and isothiazolo[5,4-d]pyrimidin-4(5H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula (I), wherein the variables R1, R2, R3, X and Z are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.
PCT/IB2008/001745 2007-06-28 2008-06-16 Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists WO2009001214A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94686507P 2007-06-28 2007-06-28
US60/946,865 2007-06-28

Publications (2)

Publication Number Publication Date
WO2009001214A2 WO2009001214A2 (en) 2008-12-31
WO2009001214A3 true WO2009001214A3 (en) 2009-07-23

Family

ID=39878037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001745 WO2009001214A2 (en) 2007-06-28 2008-06-16 Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists

Country Status (1)

Country Link
WO (1) WO2009001214A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699157A1 (en) * 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN105853415A (en) 2009-05-12 2016-08-17 罗马克实验室有限公司 Haloalkyl heteroaryl benzamide compounds
KR20170141830A (en) 2009-06-26 2017-12-26 로마크 레버러토리즈, 엘.씨. Compounds and methods for treating influenza
KR101735868B1 (en) 2010-02-17 2017-05-15 다케다 야쿠힌 고교 가부시키가이샤 Heterocyclic compound
EP2413139B1 (en) 2010-07-30 2015-05-20 Universität Leipzig Method and compositions for the identification of agents that have a potential effect against chronic inflammatory diseases
TW201219401A (en) * 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
ES2963218T3 (en) 2011-12-28 2024-03-25 Global Blood Therapeutics Inc Intermediates to obtain substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2902711C (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin
CN111454200A (en) 2013-03-15 2020-07-28 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
US20160083343A1 (en) 2013-03-15 2016-03-24 Global Blood Therapeutics, Inc Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TWI778983B (en) 2016-10-12 2022-10-01 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN107235994B (en) * 2017-08-16 2019-05-03 石家庄学院 Simultaneously [3,2-a] pyrimidine -3- acetamide derivative and the application of 5,7- diphenyl -5H- thiazole
CN107501299B (en) * 2017-09-06 2019-07-16 石家庄学院 Simultaneously [3,2-a] pyrimidine -2- carboxamides derivatives and the application of 5,7- diphenyl -5H- thiazole
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
CN113930791B (en) * 2021-10-15 2023-11-03 阜阳师范大学 Electric synthesis method of pyrido-bipyrimidine tetraketone compound

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A1 (en) * 1988-03-02 1990-04-25 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
WO2005032527A2 (en) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy
WO2005061518A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006078574A2 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2007076085A2 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc . Fused pyrimidones and thiopyrimidones, and uses thereof
WO2008012413A2 (en) * 2006-07-27 2008-01-31 Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) Pyrimidinone derivatives and their use as a drug
WO2008064018A1 (en) * 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364598A1 (en) * 1988-03-02 1990-04-25 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno ¬2,3-d pyrimidine compounds and pharmaceutical application thereof
WO2004041755A2 (en) * 2002-11-04 2004-05-21 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
WO2005032527A2 (en) * 2003-06-10 2005-04-14 Solvay Pharmaceuticals B.V. Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy
WO2005061518A1 (en) * 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2006078574A2 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2007076085A2 (en) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc . Fused pyrimidones and thiopyrimidones, and uses thereof
WO2008012413A2 (en) * 2006-07-27 2008-01-31 Societe De Conseils De Recherches Et D'applications Scientifique (S.C.R.A.S.) Pyrimidinone derivatives and their use as a drug
WO2008064018A1 (en) * 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY Chemical Abstracts Database; 2002, XP002502922 *
GADAD A K ET AL: "SYNTHESIS AND ANTIHYPERLIPAEMIC ACTIVITY OF SOME 2-AMINOMETHYL-3-ARYL-5,6,7,8-TETRAHYDROBENZO(b)/5,6-DIMETHYLTHIENO(2, 3-d)-PYRIMIDIN-4-ONES", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 46, no. 10, 1 January 1996 (1996-01-01), pages 981 - 988, XP002960408, ISSN: 0004-4172 *
GRONOWITZ S ET AL: "On thiophene analogues of metaqualonelike compounds", ACTA PHARMACEUTICA SUECICA, XX, vol. 5, 1 January 1968 (1968-01-01), pages 563 - 578, XP008098399, ISSN: 0001-6675 *
KULSHRESHTHA M J ET AL: "SYNTHESIS OF 2-METHYL, 3-ARYL OR ARYLALKYL 5,6-DIMETHYL OR POLYMETHYLENE THIENO Ä2,3-DÜ-PYRIMIDINE-4-ONES", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 58, no. 10, 1 October 1981 (1981-10-01), pages 982 - 984, XP008047632, ISSN: 0019-4522 *
RIED, W.; KAHR, E.;: "Zur Kenntnis einiger Thienopyrimidone", LIEBIGS ANNALEN DER CHEMIE, vol. 716, 1968, pages 219 - 221, XP002502704 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447071B2 (en) 2014-02-07 2016-09-20 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Also Published As

Publication number Publication date
WO2009001214A2 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009001214A3 (en) Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
WO2008041118A3 (en) Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
CL2008001899A1 (en) Compounds derived from pyrido [4,3-b] -indole fused, cathepsin k inhibitors; pharmaceutical composition; preparation procedure; and use of the compound in the treatment of diseases such as osteoporosis, osteoarthritis, rheumatoid arthritis and bone metastatic diseases, among others.
MX2009003875A (en) Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain.
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
WO2007124181A3 (en) Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2010131922A3 (en) Amide compound, preparation method thereof and pharmaceutical composition comprising same
TW200720279A (en) Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2(3H)-one derivatives
NO20081128L (en) 4-phenyl-6-substituted-pyrimidine-2-carbonitrile
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
WO2005026126A1 (en) Crf antagonists and heterobicyclic compounds
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
UA90707C2 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
EP1912639A2 (en) Thiazolopyrimidine kinase inhibitors
MX9702731A (en) Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists.
HK1091200A1 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists
EA200801529A1 (en) CRYSTAL FORMS OF 1-BENZOIL-4- [2- [4-METHOXI-7- (3-METHYL-1H-1,2,4-1-IL) -1 - [(PHOSPHONOXY) METHYL] -1H-PIRROLO [2 , 3-C] PYRIDIN-3-IL] -1,2-DIOXOETHYL] PIPERAZINE
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
MX2023000580A (en) 7-(piperidin-1-yl)-4h-pyrimido[1,2-b]pyridazin-4-one derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4.
WO2002022616A3 (en) Alpha v integrin receptor antagonists
AU2001277752A1 (en) Calcium receptor antagonists
WO2005118528A3 (en) Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions
AU2002245005A1 (en) Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776321

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08776321

Country of ref document: EP

Kind code of ref document: A2